Intravenous Dofetilide Administration for Cardiovascular Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cardiovascular conditions such as atrial fibrillation and ventricular tachycardia using dofetilide are limited by the lack of approved parenteral administration methods, necessitating the development of effective intravenous administration protocols that account for individual patient factors like creatinine clearance and QT interval monitoring.
Innovation Solution
Administering dofetilide intravenously as a loading dose over 10 minutes, followed by oral or IV maintenance doses, with dosing adjusted based on creatinine clearance and QT interval monitoring to ensure safe and effective conversion to sinus rhythm, while allowing for cardiac resuscitation and electrocardiographic monitoring.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Speed
If dofetilide is administered intravenously, then rapid onset and effective treatment of cardiovascular conditions is achieved, but the risk of adverse effects and QT interval prolongation increases
Solution Approach 1:
The patent implements preliminary actions by requiring baseline QT interval measurement before administration, assessing creatinine clearance before dosing, and having monitoring equipment ready during the infusion. These preparatory measures enable safe intravenous administration while mitigating the risk of adverse effects through proactive risk assessment and monitoring.
Solution Approach 2:
The patent employs feedback mechanisms by continuously monitoring QT interval during intravenous dofetilide administration and adjusting the infusion rate or discontinuing the drug if QT prolongation exceeds predetermined thresholds. This real-time feedback loop allows rapid response to adverse effects while maintaining therapeutic benefit.
2Reliability
If intravenous administration protocol is implemented, then treatment effectiveness is improved, but monitoring complexity and facility requirements increase
Solution Approach 1:
The patent implements self-service monitoring by establishing clear criteria for QT interval assessment and creatinine clearance evaluation that can be performed using standard medical equipment and protocols. The monitoring protocol is designed to be executed by trained healthcare professionals using readily available tools, reducing the need for specialized complex monitoring systems while ensuring reliable treatment effectiveness.
3Object-affected harmful factors
If dosing is adjusted based on creatinine clearance and QT interval, then safety is improved, but dosing complexity increases
Solution Approach 1:
The patent applies parameter changes by establishing specific threshold values for creatinine clearance and QT interval that trigger different dosing regimens. For example, dosing is reduced or adjusted when creatinine clearance falls below predetermined thresholds or when QT interval prolongation exceeds specified limits. This approach simplifies the dosing complexity by using clear, objective parameter thresholds rather than complex continuous adjustment algorithms.
Data Source
AI summary
Methods of administering dofetilide in an amount effective for treating a cardiovascular condition are described. An initial IV dose can be administered over a period of about 10 minutes to a patient/subject admitted to a medical facility providing cardiac monitoring. The patient/subject can be administered one or more oral or IV maintenance doses before or after being discharged from the medical facility. The IV dosage can be administered in a manner such that maximum serum concentration of dofetilide is reached during the administering of the IV loading dose.